HBV + C295 ISS-PMXB VACCINE IN BABOONS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objective of this experiment is to assess the dose response of a new formulation consisting of C295-PMXB in combination with HBV surface antigen. This experiment will help determine the optimal dose of C295-PMXB for increased immunogenicity of HBV antigen in adult baboons. This study will consist of 4 groups of 5 animals per group. This experiment will help determine if C295 ISS-PMXB can enhance the immune response to HBV surface antigen, and the optimal dose of C295 ISS-PMXB for enhanced immune response in baboons. This new HBV vaccine (HBV+ C295 ISS-PMXB) may be beneficial to society, since it could improve responses to HBV surface antigen, especially in poor responders to currently approved hepatitis B vaccines. C295 ISS-PMXB formulation (1000 ?g C295) has been previously tested in baboons in combination with Prevnar vaccine (ongoing study 952-PC-0). However, the C295 ISS-PMXB formulation in combination with HBV vaccine antigen has never been tested in baboons.